Citations

Clear

141 citation(s) found for "Slack, S".

Estrogen Replacement Therapy and Postoperative Complications After Distal Radius Open Reduction and Internal Fixation
Alhankawi, Ahmad R., Holle, Alejandro M, Koschmeder, Katelyn T., Lin, Eugenia, Renfree, Kevin J. , Alhankawi, Ahmad R. , Braithwaite, Collin , Holle, Alejandro M. , Koschmeder, Katelyn , Lin, Eugenia

Mayo Clinic

Orthopedics | March 26, 2026 | Volume: 49 | Issue: 2 | Pages: No page available

10.3928/01477447-20260311-01 | PMID 41885511 Get It

Background: To our knowledge, there are no studies assessing associations between patients on preoperative estrogen replacement therapy (ERT) undergoing distal radius open reduction and internal fixation (DRORIF) and postoperative outcomes. Thus, the purpose of this study was to compare surgical and medical complications in patients on ERT undergoing DR-ORIF with a matched control cohort. Materials and Methods: The PearlDiver Mariner database was searched for female patients who took ERT within 3 months of the index procedure. Patients were matched 1:4 with non-ERT controls using propensity score matching. Complications were assessed at 90 days, 2 years, and 5 years. Statistical analyses were conducted using odds ratios (OR) with 95% confidence intervals (CI). Statistical significance was determined at a P value of <.05. Results: The ERT cohort consisted of 1,815 ERT users, and the control cohort consisted of 7,247 patients. At 2 years, the ERT cohort was associated with a slightly greater incidence of malunion/nonunion (OR, 1.57; 95% CI, 1.13–2.18) but with no increased risk of revision surgery (OR, 1.10; 95% CI, 0.50–2.10). Similarly, at 5 years, the ERT cohort was associated with a slightly higher likelihood of a malunion/nonunion diagnosis (OR, 1.69; 95% CI, 1.24–2.30). Conclusion: The current study suggests that patients on preoperative ERT had a slightly increased risk of malunion/nonunion at 2 years and 5 years after DR-ORIF. We did not find associations between increases in the risk of any other major or minor complications and the cohort of patients on preoperative ERT within 5 years postoperatively.
The miR-362-3p/ BCLAF1 axis regulates cisplatin sensitivity and metastatic progression in triple-negative breast cancer
Liu, Zhaoji, Wu, Catherine, Uyemura, Madison M., Sardella, Barbara, Aronson, Emily K, Ke, Shizhong, Massicott, Erica S., Li, Xiaohui, Wang, Lin, Karagkouni, Dimitra, Kalavros, Nikolaos , Bogsan, Cristina S, Zhou, Lihan, Cheng, He, Garber, Judy E, Schnitt, Stuart J. , Tung, Nadine M, Heng, Yujing J., Heng, Yujing J. , Wu, C., Aronson, Emily K., Ke, Shizhong, Li, Xiaohui, Wang, Lin , Karagkouni, Dimitra , Vlachos, Ioannis S. , Batalini, Felipe , Bogsan, Cristina Stewart Bittencourt , Cheong, Jit Kong , Munson, Phillip B. , Mayer, Erica L. , Garber, Judy E. , Tung, Nadine , Kasinski, Andrea L. , Slack, Frank John , Wulf, Gerburg M.

Mayo Clinic

No container title available | March 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.09.26347941 Get It

Abstract Platinum-based chemotherapy remains a cornerstone of treatment for triple-negative breast cancer (TNBC), yet the molecular determinants governing platinum response remain poorly defined. By leveraging the randomized Phase II INFORM trial, which compared neoadjuvant cisplatin to anthracycline-based therapy in BRCA1/2 -mutant breast cancer—we identified miR-362-3p as a specific regulator of cisplatin sensitivity. Higher plasma miR-362-3p expression was exclusively associated with favorable clinical outcome in the cisplatin arm, with no association observed in the AC arm, decoupling platinum-specific vulnerability from general chemotherapy response. We used gain- and loss-of-function TNBC models to establish that miR-362-3p functions as a potent sensitizer to cisplatin in vitro and in vivo . Integrated TCGA analysis and experimental validation identified BCLAF1, a key regulator of DNA damage response, as a direct repression target of miR-362-3p. We uncovered a novel role for the miR-362-3p/ BCLAF1 axis in overcoming platinum resistance in TNBC.
Factors Affecting Nurses' Ability to Identify Delirium in Acute Care Settings
Hook, Mary L., Lindroth, Heidi L., McGuire, Dana, Reopelle, Stephanie L, Strand, Stephanie A., Jacobson, Nora , Hook, Mary L. , Lindroth, Heidi

Mayo Clinic

Research in Gerontological Nursing | March 9, 2026 | Volume: 19 | Issue: 3 | Pages: 109-121

10.3928/19404921-20260303-02 | PMID 41800940 Get It

Purpose: Delirium is a serious underrecognized health condition in hospitalized older adults. The current qualitative study used dimensional analysis to increase understanding of the clinical reasoning processes used by acute care nurses to assess for delirium. Method: Ten focus groups with experienced medical, surgical, and intensive care nurses ( N = 39) from quaternary, community, and academic medical centers discussed their application of clinical reasoning processes to assess/detect delirium symptoms. Transcripts were inductively analyzed. Trustworthiness was checked with a subset of participants ( n = 12). Results: Findings illustrate how nurses apply clinical reasoning to recognize and respond to delirium symptoms and navigate clinical and social structures to maintain patient safety. Clinical context and social structures are important conditions influencing nurse reasoning and judgment. Conclusion: Further process improvement and research efforts should explore strategies to enhance interdisciplinary shared knowledge within a supportive environment to improve the detection and care to lessen the severity and duration of delirium for vulnerable patients.
Answers to Common Questions About Postural Orthostatic Tachycardia Syndrome and Chronic Orthostatic Intolerance
Mauriello, Daniel, Mitchell, Brooke, Klaas, Kelsey

Mayo Clinic

Pediatric Annals | March 5, 2026 | Volume: 55 | Issue: 3 | Pages: No page available

10.3928/19382359-20260112-04 | PMID 41784480 Get It

How is postural orthostatic tachycardia syndrome (POTS) diagnosed? What about adolescents who seem to have POTS but do not meet the diagnostic criteria? How can we treat POTS and related conditions? How can we best respond to common questions of frustrated patients and parents and guardians? This article provides evidence- and expert-based answers to questions that frequently arise when caring for patients with POTS and related conditions.
Postural Orthostatic Tachycardia Syndrome and Chronic Orthostatic Intolerance: Common, Challenging, and Manageable
Klaas, Kelsey , Fischer, Philip R.

Mayo Clinic

Pediatric Annals | March 5, 2026 | Volume: 55 | Issue: 3 | Pages: No page available

10.3928/19382359-20260112-02 | PMID 41784482 Get It

Dedicated Education Units and Traditional Learning Models: A Systematic Review
Gangeness, Jeanine E., Benike, Linnea, Monteau, Rebecca E. , Gerberi, Dana , Benike, Linnea A

Mayo Clinic

Journal of Nursing Education | January 15, 2026 | Volume: 65 | Issue: 1 | Pages: 33-38

10.3928/01484834-20250926-01 | PMID 41537789 Get It

Background: This systematic review examined differences in learner outcomes between traditional learning models (TLMs) and dedicated education units (DEUs) in undergraduate nursing programs. Method: Six databases were searched to identify peer-reviewed literature published between 2000 and 2025. Fifteen articles informed this review. Results: Included studies focused on various student outcomes including evaluation of students' perceptions and student performance. Themes around student perception included learning environment, learning opportunities, and learning performance. Themes around performance included standardized exams, course exams, competency exams, and preceptor evaluation of competency development. Conclusion: Main findings indicate the DEU model for clinical education enhances student satisfaction with the learning environment, increases learning opportunities, and improves self-perceived learning performance. The effects of DEUs on student performance outcomes require additional research, but preliminary research suggests a positive relationship between the DEU and competency development.
Gene expression profiling reveals 2 overarching types of ALCL with distinct targetable biology: an LLMPP study
Feldman, Andrew L. , Dasari, Surendra, Scott, David W. , Oishi, Naoki , Hu, Guangzhen , Farinha, Pedro , Amador, Catalina , Campo, Elı́as , Cook, James R. , Fu, Kai , Greiner, Timothy C. , Iqbal, Javeed , Ondrejka, Sarah L. , Ott, G., Rosenwald, Andreas , Slack, Graham W. , Wright, George, Zeng, Yu , Yoshino, Tadashi, Wu, Xiaojun , Satou, Akira , Perry, Anamarija M. , Mou, Eric , Ko, Young Hyeh , Jiang, Liuyan , Gru, Alejandro A. , Chen, Weina , Chapman, Jennifer R. , Ansell, Stephen M. , Aljudi, Ahmed Assim , Scott, David W , Oishi, Naoki , Farinha, Pedro , Amador, Catalina , Campo, Elías , Cook, James R , Delabie, Jan , Greiner, Timothy C , Hilton, Laura K , Inghirami, Giorgio , Jaffe, Elaine S , Morin, Ryan D , Ondrejka, Sarah , Pittaluga, Stefania , Savage, Kerry J , Slager, Susan L , Wang, Hao-Wei , Wu, Xiaojun , Wilcox, Ryan A , Shi, Min , Miranda, Roberto N , Medeiros, L Jeffrey , Maurer, Matthew , Mou, Eric , Karube, Kennosuke , Gru, Alejandro , de Leval, Laurence , Chen, Weina , Cerhan, James R , Barrionuevo, Carlos , Aljudi, Ahmed Assim , Feldman, Andrew L , Iqbal, Javeed , Rimsza, Lisa M. , Chan, Wing C., Delabie, Jan , Hilton, Laura K. , Inghirami, Giorgio , Jaffe, Elaine S. , Pittaluga, Stefania , Raess, Philipp W. , Savage, Kerry J. , Slager, Susan L. , Song, Joo Y. , Wang, Hao‐Wei , Wilcox, Ryan A. , Wang, Xueju , Miranda, Roberto N. , Medeiros, L. Jeffrey , Maurer, Matthew J. , Karube, Kennosuke , Kahl, Brad S. , Jaye, David L. , Leval, Laurence de , Cerhan, James R.

Mayo Clinic

Blood | December 2, 2025 | Volume: 147 | Issue: 11 | Pages: 1199-1214

10.1182/blood.2024027700 | PMID 41329859 Get It

Abstract Anaplastic large cell lymphomas (ALCLs) are CD30+ T-cell lymphomas that share pathologic features but differ in presentation, outcome, and genetics. Current classification incorporates clinical presentation and anaplastic lymphoma kinase (ALK) status but inadequately addresses molecular heterogeneity and therapeutic vulnerabilities. We studied 689 patients with ALCL in the LLMPP (Lymphoma/Leukemia Molecular Profiling Project) and performed expert consensus review, genetic subtyping (ALK, DUSP22, TP63, and triple negative), and immunohistochemistry for phosphorylated STAT3Tyr705. RNA sequencing with unsupervised gene expression profiling in 393 patients identified 2 main molecular types of ALCL that could be predicted with 91% accuracy based on the presence (type I) or absence (type II) of phosphorylated STAT3Y705 expression. Type I ALCLs included ALK+ ALCL and a subset of triple-negative ALCLs (TN-I); type II ALCLs included tumors with DUSP22 and/or TP63 rearrangements and the remaining triple-negative ALCLs (TN-II). Type I ALCLs were enriched for JAK-STAT3, whereas type II ALCLs were enriched for non–tyrosine kinase pathways, particularly epigenetic regulators such as EZH2. Immunohistochemistry showed overexpression of EZH2 and its trimethylated substrate H3K27. Prognosis in systemic ALCL was favorable for DUSP22-rearranged ALCL (5-year overall survival, 95%) and ALK+ ALCL (88%), intermediate for triple-negative ALCL (TN-I, 52% and TN-II, 37%), and poor for TP63-rearranged ALCL (0%). We introduce an integrated molecular classification that preserves currently diagnosed ALCL entities but identifies 4 molecularly distinct ALK− ALCL subtypes (DUSP22-rearranged, TP63-rearranged, TN-I, and TN-II). This classification can be easily implemented on paraffin tissue in routine practice or clinical trials, and stratifies ALCL into diagnostically, prognostically, biologically, and potentially therapeutically relevant subtypes.
Prevalence of Cannabidiol (CBD) Use in an Outpatient Hand Surgery Clinic
Deckey, David G. , Ishimoto, A., Renfree, Sean P. , Noland, Shelley S. , Iturregui, Jose M. , Ishimoto, Alyssa, Renfree, Kevin J.

Mayo Clinic

Orthopedics | October 20, 2025 | Volume: 48 | Issue: 6 | Pages: 329-335

10.3928/01477447-20250904-01 | PMID 41114690 Get It

Background: The aim of this study was to evaluate the prevalence and perceived efficacy of cannabidiol (CBD) products in patients presenting to an orthopedic hand and upper extremity clinic. Materials and Methods: New patients seen for an initial surgical consultation between July and December 2022 were surveyed regarding CBD use, pain, and function. Pain was measured with the Numeric Pain Rating Scale (NPRS, 0–10) and function with the Single Assessment Numeric Evaluation (SANE, 0–100). Demographic and clinical factors were collected via chart review. Results: A total of 918 patients completed the survey (53% female; mean age 63 years, range 18–97). Joints involved included elbows (106), wrists (335), and hands/fingers (667). Common diagnoses included arthritis (199), tendinopathy (273), and nerve-related conditions (160). Overall, 15% (135/918) reported prior CBD use, and 39% (53/135) perceived pain relief. CBD users were more likely to be female (65% vs 51%; P =0.003), to present with wrist pathology (44% vs 35%; P =0.038), and to have arthritis (36% vs 19%; P <0.001). Compared to non-users, CBD users reported higher pain scores (mean NPRS 6.2 vs 5.1; P <0.001) and lower contralateral function (mean SANE 77.3 vs 87.4; P <0.001). Conclusions In this cohort, CBD use was uncommon, and only a minority of users reported subjective benefit. CBD users tended to report higher pain and worse function, particularly in the setting of wrist arthritis. CBD products did not appear to provide measurable objective improvement in pain or function. Further studies are needed to clarify optimal dosing, administration, and potential role in upper extremity care.
Trends and Outcomes of Secondary Intraocular Lens Utilization Among Vitreoretinal Surgeons Compared to Vitreoretinal and Anterior Segment Surgeons
Aggarwal, Nitika, Boucher, Nicholas, Sharma, Chakshu, Bantounou, Maria Anna , Boucher, Nicholas, Starr, Matthew R.

Mayo Clinic

Ophthalmic Surgery, Lasers and Imaging Retina | September 15, 2025 | Volume: 56 | Issue: 10 | Pages: 602-607

10.3928/23258160-20250725-01 | PMID 40952683 Get It

Background and Objective: Scleral-fixated intraocular lens (SFIOL), scleral-sutured IOL (SSIOL), anterior chamber IOL (ACIOL) are used to manage aphakia or lens subluxation. This study compared trends in surgical techniques and outcomes of secondary IOL implantation based on surgeon type. Patients and Methods: This retrospective study included patients from United States (US) retinal centers who underwent surgery by vitreoretinal (VR cohort) or VR and anterior segment (AS) (combined cohort) surgeons from 2015 to 2024. Complications assessed included retinal detachment, endophthalmitis, suture erosion, haptic erosion, repeat pas plana vitrectomy, and corneal edema. Results: VR surgeons performed 4,143 secondary IOL surgeries (1,977 ACIOL, 1,327 SFIOL, 839 SSIOL) while VR and AS surgeons performed 511 (342 ACIOL, 125 SFIOL, 44 SSIOL). SFIOL and SSIOL surgeries by VR surgeons increased, whereas ACIOL surgeries decreased. VR and AS surgeons maintained a steady but lower volume of SFIOL and SSIOL cases, with increasing ACIOL surgeries. Postoperative visual acuity for the VR and combination cohorts was 54.3 ± 27.8 and 51.5 ± 27.2 (≈ 20/100 Snellen) ( P value = 0.102), respectively. Complication rates were similar between cohorts, except for postoperative retinal detachment (VR: 144, 3.5%; combined: 26, 5.1%; P value < 0.001). Conclusion: ACIOLs were the most commonly performed secondary IOL surgery. However, a shift toward SFIOL and SSIOL techniques among vitreo-retinal surgeons emerged. Outcomes were comparable between approaches.
High-grade B-cell lymphoma, not otherwise specified: an LLMPP study
Collinge, Brett , Hilton, Laura K. , Wong, Jasper , Alduaij, Waleed , Ben‐Neriah, Susana , Slack, Graham W. , Farinha, Pedro , Boyle, Merrill, Meissner, Barbara , Cook, James R. , Ott, G., Rosenwald, Andreas , Amador, Catalina , Greiner, Timothy C. , Ondrejka, Sarah L. , Weisenburger, Dennis D. , Beiske, Klaus , Fu, Kai , Iqbal, Javeed , Wright, George, Staudt, Louis M. , Boyle, Merrill , Campo, Elías , Amador, Catalina , Greiner, Timothy C , Inghirami, Giorgio , Ondrejka, Sarah , Jaffe, Elaine S , Holte, Harald , Delabie, Jan , Pittaluga, Stefania , Savage, Kerry J , Mungall, Andrew J , Steidl, Christian , Feldman, Andrew L , Morin, Ryan D , Scott, David W , Iqbal, Javeed , Alduaij, Waleed , Farinha, Pedro , Hilton, Laura K , Campo, Elı́as , Raess, Philipp W. , Song, Joo Y. , Inghirami, Giorgio , Jaffe, Elaine S. , Chan, Wing C., Holte, Harald , Delabie, Jan , Pittaluga, Stefania , Savage, Kerry J. , Mungall, Andrew J. , Steidl, Christian , Feldman, Andrew L. , Rimsza, Lisa M. , Scott, David W.

Mayo Clinic

Blood Advances | July 17, 2025 | Volume: 9 | Issue: 21 | Pages: 5409-5422

10.1182/bloodadvances.2025016651 | PMID 40674706 Get It

Abstract Molecular characterization of high-grade B-cell lymphoma, not otherwise specified (HGBCL-NOS), is hindered by its rarity, evolving definition, and poor diagnostic reproducibility. To address this challenge, we analyzed 92 HGBCL-NOS tumors collected across Lymphoma/Leukemia Molecular Profiling Project sites. Leveraging comparison cohorts of diffuse large B-cell lymphoma, NOS (DLBCL-NOS) and Burkitt lymphoma (BL), and molecular frameworks described in these entities, our analysis revealed a heterogenous molecular landscape, reminiscent of DLBCL-NOS but with an enrichment of BL features. By cell-of-origin classification, 59% were germinal center B-cell–like (GCB), and 25% were activated B-cell–like (ABC). LymphGen, a genetic classifier for DLBCL-NOS, assigned a genetic subtype to 34% of HGBCL-NOS. Although classification rate was lower than in DLBCL-NOS (66%), assigned subtypes spanned the spectrum of LymphGen classes, including 31% of ABCs classified as MCD. Features differentiating HGBCL-NOS from DLBCL-NOS included MYC rearrangement (47% vs 6%); dark zone signature (DZsig) expression (45% vs 7%); and more frequent mutation of ID3, MYC, CCND3, and TP53, all common to BL. A genetic classifier that differentiates DLBCL-NOS from BL classified 53% of DZsig+ tumors as BL-like, and those classified as DLBCL-like were frequently BCL2-rearranged. Among DZsig− GCB tumors, 95% were DLBCL-like. Centralized pathology review reclassified almost half of tumors as DLBCL-NOS but did not identify a more homogenous HGBCL-NOS population, with no difference in features between confirmed and reclassified tumors. In conclusion, molecular testing enables a subset of HGBCL-NOS to be assigned to established categories. Based on rarity and diagnostic challenges, broader inclusion of HGBCL-NOS should be considered in biomarker-driven DLBCL trials.